| DB ID | MyCo_6051 |
| Title | Levels of interleukin (IL)-6 and IL-8 are elevated in serum and bronchoalveolar lavage fluid of haematological patients with invasive pulmonary aspergillosis |
| Year | 2017 |
| PMID | 28877383 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study protocol was approved by the local ethics committees, Medical University Graz, Austria (EC-numbers 25- |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | IL-6 |
| Biomarker Full Name | Interleukin-6 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Austria |
| Cohort | This nested case-¬ control study of prospectively collected data com- prised paired routine serum and BALF samples obtained on the same day from 10 cases with IPA and 20 matched controls without IPA. |
| Cohort No. | 10 Patients and 20 control |
| Age Group | 26-73 |
| P Value | p=.011 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive pulmonary aspergillosis (IPA) is associated with high morbidity and mortality among patients with underlying haematological malignancies. Due to the crude mortality of 80%-¬ 90% in the absence of adequate treatment, timely diagnosis and early start of antifungal therapy are key factors in the successful treatment of IPA. The introduction of non-¬ cultural diagnostic tests for IPA in blood and bronchoalveolar lavage fluid (BALF), including galactomannan antigen (GM) testing, PCR, the Aspergillus specific lateral flow device test and 1,3-¬ β- d- glucan (BDG) testing, was associated with a significant increase in the rate of IPA-¬ diagnosed premortem (vs postmortem). Despite these significant advancements, performance of these non-cultural diagnostic tests is varying, and the search for a reliable gold standard for diagnosis of IPA premortem continues. |
| Technique | Immunological assay |
| Analysis Method | ProcartaPlex® 11plex immunoassay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ProcartaPlex® 11plex immunoassay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
